Compare ARK Genomic Revolution ETF (ARKG) vs Entegris Inc (ENTG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Entegris Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Entegris Inc trades at $141.29 (market cap $22.14B). The key difference: Entegris Inc pays a 0.28% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Entegris Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | ENTG | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $184.00 |
52-Week Low | $23.09 | $68.80 |
Market Cap | — | $22.14B |
Enterprise Value | — | $25.45B |
Dividend Yield | — | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
ENTG trades at $145.35, down 0.51% today, with technical indicators showing a bearish trend and support at $143. The company reported Q1 2026 EPS of $0.86, beating estimates, but maintains premium valuations with a P/E of 84.02. Revenue has been stable around $3.2B annually, with net income margins improving to 8.18% in 2026. Analyst sentiment remains positive with a $178.40 price target, though recent news highlights volatility and valuation concerns.
Outlook: ENTG benefits from semiconductor industry tailwinds and AI-driven demand, but faces risks from high valuation and market volatility. The stock offers potential upside based on analyst targets, but investors should monitor earnings consistency and competitive pressures in the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
